Cardax Inc · OTC:CDXI
Cardax — Investor Presentation (June 2015)
35 slides from Cardax's investor presentation, June 2015
Slide 1: Corporate Presentation
Corporate Presentation Updated June 2015
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer There are statements in this presentation that are not historical facts. These “forward-looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “p
Slide 3: Cardax: Focusing on the Source of Inflammation
Cardax: Focusing on the Source of InflammationTM Cardax is developing astaxanthin therapies for large unmet medical needs where inflammation and oxidative stress play key causative roles. CARDAX IN BRIEF Cardax is focusing first on developing products utilizing astaxanthin, a naturally occurring c
Slide 4: Strategic Alliances
Strategic Alliances Efficient, scalable, and economical path to mass markets not available to low-volume agricultural astaxanthin producers B A S F – T H E W O R L D ’ S L A R G E S T C H E M I C A L C O M PA N Y Cardax and BASF have a Joint Development and Supply Agreement related to the developm
Slide 5: Strategic Alliances Cont.
Strategic Alliances Cont. Increased oral bioavailability of nature-identical astaxanthin for consumer health applications C A P S U G E L – G L O B A L F O R M U L AT I O N L E A D E R In 2014, Cardax and Capsugel entered into a Collaboration Agreement for the joint development of astaxanthin prod
Slide 6: Strategic Milestones
Strategic Milestones P O T E N T I A L VA L U E - C R E AT I O N E V E N T S A N D A C T I V I T I E S BASF launch of astaxanthin consumer health product(s) (“BASF Astaxanthin Products”); Cardax royalty‐stream from sales of BASF Astaxanthin Products. Launch of astaxanthin consumer health product
Slide 7: Board of Directors
Board of Directors N I C H O L A S M I T SA KO S , E X EC U T I V E C H A I R M A N Chairman and CEO of Arcadia Holdings, Inc., focusing on private equity investments globally. Arcadia’s financial partners include Trust Company of the West, a $150B investment company, and Canyon Partners, a $20B hed
Slide 8: Board of Directors Cont.
Board of Directors Cont. T E R E N C E A . K E L LY, P H . D . , D I R E C T O R Nearly 20 years in scientific and executive positions at Boehringer Ingelheim, including VP, Department of Medicinal Chemistry; led 145 scientists in the high throughput screening, computational chemistry, structural bi
Slide 9: Senior Management Team
Senior Management Team D A V I D G . W AT U M U L L , P R E S I D E N T & C E O , D I R E C T O R More than twenty years industry experience as a biotechnology executive, analyst, and investment banker. Co-founder of Cardax and co-inventor of Cardax’s technology. Conceived and led development of fir
Slide 10: Senior Management Team Cont.
Senior Management Team Cont. TIMOTHY KING, PH.D., VP RESEARCH Former Staff Scientist at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington, Dr. King has over 22 years of combined academic and private sector scientific research experience including utilizing cell culture and an
Slide 11: Intellectual Property
Intellectual Property Cardax has a robust intellectual property portfolio that offers a valuable competitive advantage. PAT E N T P O R T F O L I O Cardax patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of its Astaxanthin and related products in certain
Slide 12: Inflammation and Disease
Inflammation and Disease Cardax’s pharmaceutical development program will target conditions where inflammation and oxidative stress are strongly implicated. C O N D I T I O N S TA R G E T E D Osteoarthritis Cognitive Decline Metabolic Syndrome Liver Disease (NASH, ASH) Cardiovascular Disea
Slide 13: Inflammation and Disease Cont.
Inflammation and Disease Cont. Inflammation is the body's natural response to injury, irritants, and pathogens – chronic inflammation may occur when the immune system does not function properly and increases disease risk. C H R O N I C I N F L A M M AT I O N Excess oxidative stress inside cells at
Slide 14: Astaxanthin Fights Inflammation at its Source
Astaxanthin Fights Inflammation at its Source Astaxanthin reduces the oxidative stress that initiates and perpetuates the chronic and pathological activation of a number of inflammatory pathways. MECHANISM OF ACTION Astaxanthin spans plasma, mitochondrial, and nuclear membranes of the targeted tis
Slide 15: Astaxanthin in Nature
Astaxanthin in Nature Astaxanthin is a naturally occurring marine compound that was found to improve animal health and vitality, prompting further scientific study. R O L E O F A S TA X A N T H I N I N T H E M A R I N E F O O D C H A I N 1 2 3 Astaxanthin is synthesized by Krill are small crustacean
Slide 16: Astaxanthin Scientific Research
Astaxanthin Scientific Research 1,000+ peer reviewed papers featuring astaxanthin have been published in leading scientific journals. RESEARCH SUPPORTS USE More than 40 human clinical trials support the safety and efficacy of astaxanthin. More than 50 peer reviewed papers published by Cardax tea
Slide 17: Astaxanthin Scientific Research Cont.
Astaxanthin Scientific Research Cont. Astaxanthin and Related Esters have demonstrated efficacy in models of inflammatory-mediated disease. D E M O N S T R AT E D E F F I C A C Y I N S C I E N T I F I C R E S E A R C H Reduction of TNF-α levels equivalent to a steroid. Reduction of liver enzymes
Slide 18: Benefits of Astaxanthin Use
Benefits of Astaxanthin Use Astaxanthin is proven to reduce inflammation at its source, without the harmful side effects of common anti-inflammatory and pain relief medications. A D VA N TA G E S O F A S TA X A N T H I N U S E Possible Side Effects of Other Anti-Inflammatory / Pain Relief Drugs Bene
Slide 19: Broader Awareness is Driving Astaxanthin Demand
Broader Awareness is Driving Astaxanthin Demand Consumer interest in astaxanthin has led to a sharp increase in demand; some manufacturer sales have doubled since 2010. A S TA X A N T H I N S E A R C H V O L U M E 2 0 0 4 – P R E S E N T Astaxanthin – Normalized Search Volume in Google Source: Googl
Slide 20: Recent Coverage of Astaxanthin in Mainstream Media
Recent Coverage of Astaxanthin in Mainstream Media SELECT MEDIA COVERAGE All registered trademarks, logos, images, and content are property of their respective owners; there is no endorsement of Cardax or any its products or technologies by any such owner.
Slide 21: Agricultural Astaxanthin
Agricultural Astaxanthin Currently, astaxanthin for consumer health use is primarily derived from low volume agricultural (microalgal) sources; agricultural producers face significant challenges to meet growing global demand. C E R TA I N I S S U E S FA C E D B Y A G R I C U LT U R A L S U P P L I E
Slide 22: "Nature-Identical" Synthetic Astaxanthin
“Nature-Identical” Synthetic Astaxanthin The Cardax-BASF JDSA will enable an efficient, scalable, and economical path to mass markets not currently available to low-volume agricultural producers. N O V E L M A N U FA C T U R I N G A P P R O A C H A proprietary and scalable manufacturing process fo
Slide 23: "Nature-Identical" Synthetic Astaxanthin Cont.
“Nature-Identical” Synthetic Astaxanthin Cont. Production of “nature-identical” synthetic astaxanthin has multiple advantages over agricultural astaxanthin. S Y N T H E T I C V S . A G R I C U LT U R A L P R O D U C T I O N Synthetic production methods can be scaled to accommodate growing global d
Slide 24: Cardax Astaxanthin: Pharmaceutical Development
Cardax Astaxanthin: Pharmaceutical Development Cardax intends to pursue the clinical development of astaxanthin as an over-the-counter drug and/or prescription drug. CLINICAL DEVELOPMENT PROGRAM Cardax plans to conduct three to five low-risk, low-cost, clinical trials after obtaining additional fi
Slide 25: Cardax Pharmaceutical Pipeline
Cardax Pharmaceutical Pipeline Cardax plans to pursue multiple indications for Cardax Astaxanthin and two other exceptionally safe, anti-inflammatory compounds from the same family, zeaxanthin and lycophyll. D I S E A S E S TAT E S TA R G E T E D Osteoarthritis Cardax Astaxanthin Cognitive Decli
Slide 26: Astaxanthin for Osteoarthritis
Astaxanthin for Osteoarthritis Cardax Astaxanthin is well positioned to meet the needs of patients suffering from osteoarthritis. OSTEOARTHRITIS OPPORTUNITY Current treatments for osteoarthritis include NSAIDs (Celebrex®, Aleve®, etc.), steroids (Prednisolone, etc.), and glucosamine/chondroitin.
Slide 27: Astaxanthin for Osteoarthritis Cont.
Astaxanthin for Osteoarthritis Cont. The Centers for Disease Control and Prevention report that the amount of direct medical expenditures in the U.S. for arthritis and other rheumatic conditions was $80.8B in 2003. OSTEOARTHRITIS MARKET OVERVIEW According to the Centers for Disease Control and Pre
Slide 28: Astaxanthin for Cognitive Decline
Astaxanthin for Cognitive Decline A human clinical trial supports the potential for Cardax Astaxanthin to improve cognitive function in an elderly population afflicted with age- related forgetfulness. COGNITIVE DECLINE OPPORTUNITY Potential treatment for an expanding population with few options to
Slide 29: Astaxanthin for Metabolic Syndrome
Astaxanthin for Metabolic Syndrome Cardax Astaxanthin could lessen the majority of physiological measures defining metabolic syndrome, and thereby decrease the risk of ensuing cardiovascular disease, diabetes, and liver disease. M E TA B O L I C S Y N D R O M E O P P O R T U N I T Y Metabolic synd
Slide 30: Selected Astaxanthin Clinical Trials
Selected Astaxanthin Clinical Trials
Slide 31: Astaxanthin Reduces Inflammation in Humans
Astaxanthin Reduces Inflammation in Humans STUDY DESIGN R E S U LT S 17 subjects at risk for metabolic TNF-α highly significantly decreased. syndrome (ages 22-65) with waist circumference (>85cm) and one of the -30%, p=0.0022 following: Adiponectin highly significantly Fasting plasma gluco
Slide 32: Clinical Efficacy of Astaxanthin in Metabolic Syndrome
Clinical Efficacy of Astaxanthin in Metabolic Syndrome STUDY DESIGN R E S U LT S 61 subjects at risk for metabolic TG levels significantly decreased. syndrome (ages 25-60): HDL-C significantly increased. Fasting triglyceride level 120- 200mg/dL (normal to borderline Adiponectin levels sign
Slide 33: Clinical Efficacy of Astaxanthin in Obese Patients
Clinical Efficacy of Astaxanthin in Obese Patients STUDY DESIGN R E S U LT S 27 obese subjects (ages 20-55): LDL-C significantly decreased (-10.4%). BMI > 25 (excluding diabetes, HDL-C non-significantly increased hypertension, cardio disease) (+6.7%). Double-blind, placebo-controlled Oxi
Slide 34: Certain Disclosures
Certain Disclosures The information contained in this Corporate Presentation (this “Presentation”) summarizes certain information about Cardax, Inc. (the “Company”) and its subsidiary Cardax Pharma, Inc. and is qualified in its entirety by, and should be considered in conjunction with, the informati
Slide 35: Cardax, Inc. Contact Details
Cardax, Inc. 2800 Woodlawn Drive, Suite 129 Honolulu, Hawaii 96822 (808) 457-1400